Intradermally injected SCCNVs could deliver tumor antigens and adjuvants (IFN-γ and TNF-α) to DCs, resulting in DC activation, DC migration to the draining lymph nodes, and activation of tumor-specific T cells capable of cancer cell killing (Fig. 1b). This evidence concerns the gene IFNG and neoplasm.